Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (137) 137
hematology (125) 125
index medicus (103) 103
female (96) 96
male (95) 95
adult (82) 82
adolescent (73) 73
middle aged (73) 73
child (59) 59
transplantation (53) 53
aged (42) 42
child, preschool (42) 42
mexico (37) 37
oncology (37) 37
therapy (35) 35
treatment outcome (35) 35
young adult (35) 35
stem cells (34) 34
infant (30) 30
leukemia (28) 28
retrospective studies (27) 27
chemotherapy (25) 25
children (24) 24
disease-free survival (24) 24
transplantation conditioning - methods (24) 24
remission induction (23) 23
hematopoietic stem cell transplantation - methods (22) 22
medicine, research & experimental (22) 22
transplantation, homologous (22) 22
analysis (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
bone marrow (20) 20
bone-marrow-transplantation (20) 20
hematopoietic stem cell transplantation (20) 20
hematopoietic stem cells (20) 20
stem-cell transplantation (19) 19
acute lymphoblastic leukemia (18) 18
rituximab (17) 17
aged, 80 and over (16) 16
antineoplastic agents - therapeutic use (16) 16
cancer (16) 16
survival analysis (16) 16
diagnosis (15) 15
hematology, oncology and palliative medicine (15) 15
care and treatment (14) 14
follow-up studies (14) 14
recurrence (13) 13
survival (13) 13
experience (12) 12
graft vs host disease - etiology (12) 12
prospective studies (12) 12
transplantation conditioning (12) 12
blood (11) 11
developing countries (11) 11
disease (11) 11
hematologic neoplasms - therapy (11) 11
prognosis (11) 11
survival rate (11) 11
acute lymphocytic leukemia (10) 10
allografts (10) 10
diseases of the blood and blood-forming organs (10) 10
immunology (10) 10
immunosuppressive agents - therapeutic use (10) 10
lymphoma (10) 10
outcomes (10) 10
pediatrics (10) 10
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (10) 10
relapse (10) 10
research (10) 10
risk (10) 10
stem cell transplantation (10) 10
time factors (10) 10
treatment (10) 10
adults (9) 9
chronic myelogenous leukemia (9) 9
efficacy (9) 9
engraftment (9) 9
hematopoietic stem cell transplantation - adverse effects (9) 9
medicine & public health (9) 9
original (9) 9
transplantation, autologous (9) 9
versus-host-disease (9) 9
acute myeloid-leukemia (8) 8
adolescents (8) 8
cyclophosphamide (8) 8
kaplan-meier estimate (8) 8
leukemia, myeloid, acute - therapy (8) 8
risk factors (8) 8
vidarabine - analogs & derivatives (8) 8
abridged index medicus (7) 7
allogeneic (7) 7
allograft (7) 7
anemia (7) 7
antithymocyte globulin (7) 7
childhood (7) 7
cyclophosphamide - administration & dosage (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - therapy (7) 7
management (7) 7
medicine, general & internal (7) 7
mexico - epidemiology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
by Experts in Chronic Myeloid Leukemia, in Chronic Myeloid Leukemia and Abboud, Camille and Berman, Ellin and Cohen, Adam and Cortes, Jorge and DeAngelo, Daniel and Deininger, Michael and Devine, Steven and Druker, Brian and Fathi, Amir and Jabbour, Elias and Jagasia, Madan and Kantarjian, Hagop and Khoury, Jean and Laneuville, Pierre and Larson, Richard and Lipton, Jeffrey and Moore, Joseph O and Mughal, Tariq and O'Brien, Susan and Pinilla-Ibarz, Javier and Quintas-Cardama, Alfonso and Radich, Jerald and Reddy, Vishnu and Schiffer, Charles and Shah, Neil and Shami, Paul and Silver, Richard T and Snyder, David and Stone, Richard and Talpaz, Moshe and Tefferi, Ayalew and Van Etten, Richard A and Wetzler, Meir and Abruzzese, Elisabetta and Apperley, Jane and Breccia, Massimo and Byrne, Jenny and Cervantes, Francisco and Chelysheva, Ekaterina and Clark, R.E and De Lavallade, Hugues and Dyagil, Iryna and Gambacorti-Passerini, Carlo and Goldman, John and Haznedaroglu, Ibrahim and Hjorth-Hansen, Henrik and Holyoake, Tessa and Huntly, Brian and Le Coutre, Philipp and Lomaia, Elza and Mahon, Francois-Xavier and Marin-Costa, David and Martinelli, Giovanni and Mayer, Jiri and Milojkovic, Dragana and Olavarria, Eduardo and Porkka, Kimmo and Richter, Johan and Rousselot, Philippe and Saglio, Giuseppe and Saydam, Guray and Stentoft, Jesper and Turkina, Anna and Vigneri, Paolo and Zaritskey, Andrey and Aguayo, Alvaro and Ayala, Manuel and Bendit, Israel and Bengio, Raquel Maria and Best, Carlos and Bullorsky, Eduardo and Cervera, Eduardo and Desouza, Carmino and Fanilla, Ernesto and Gomez-Almaguer, David and Hamerschlak, Nelson and Lopez, Jose and Magarinos, Alicia and Meillon, Luis and Milone, Jorge and Moiraghi, Beatriz and Pasquini, Ricardo and Pavlovsky, Carolina and Ruiz-Arguelles, Guillermo J and Spector, Nelson and Arthur, Christopher and Browett, Peter and Grigg, Andrew and Hu, Jianda and Huang, Xiao-jun and Hughes, Tim and Jiang, Qian and Jootar, Saengsuree and Kim, Dong-Wook and Malhotra, Hemant and Malhotra, Pankaj and Matsumura, Itaru and Melo, Junia and Ohnishi, Kazunori and ... and Experts Chronic Myeloid Leukemia and Experts in Chronic Myeloid Leukemia
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 22, pp. 4439 - 4442
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the... 
WORTH | COST-EFFECTIVENESS | THERAPY | HEMATOLOGY | ERA | QUESTION | Drug Costs - trends | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics | Drug Industry - economics | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drugs, Generic - economics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - economics | Patents as Topic | Forum
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Contributions to Global Hematology from Low and Middle-Income Countries: Insights from ASH 2018
by Gómez-De León, Andrés and Colunga Pedraza, Perla R and Tarín Arzaga, Luz del Carmen and Bugarin-Estrada, Emmanuel and Gómez-De León, David and Sung, Lillian and Gomez-Almaguer, David
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2123 - 2123
Background. Establishing research capacity in low and middle-income countries (LMIC) is key for improving health systems and implementing actionable programs... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Case of Concordant Acute Myeloblastic Leukemia in Identical Twins Treated with Allogeneic Transplantation From an HLA-Identical Infant Donor Following a Single Apheresis Procedure and Performed in an Outpatient Setting
by Gómez-Almaguer, David and Llano, Oscar Gonzalez and Cantu, Marcela
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 23, Issue 3, pp. S271 - S272
Hematology, Oncology and Palliative Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cyclophosphamide, Gemcitabine, Vinorelbine and Prednisone (CGEV) As Salvage Therapy for Relapsed or Refractory Hodgkin´s Lymphoma before Hematopoietic Stem Cell Transplantation: A Single Center Experience
by Cárdenas-Araujo, Daniela and Gonzalez-Leal, Xitlaly Judith and Gomez-Almaguer, David
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1523 - 1523
Abstract Background and Objectives: Although the therapy of advanced-stage Hodgkin Lymphoma (HL) has improved, up to 10% of patients with advanced-stage HL... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Eltrombopag-based combination treatment for immune thrombocytopenia
by Gomez-Almaguer, D
THERAPEUTIC ADVANCES IN HEMATOLOGY, ISSN 2040-6207, 10/2018, Volume 9, Issue 10, pp. 309 - 317
Immune thrombocytopenia (ITP) is a bleeding disorder caused by a decrease in platelet count resulting from increased destruction and insufficient production of... 
TERM TREATMENT | EFFICACY | immune thrombocytopenia | PURPURA | ADULTS | RECOMBINANT HUMAN THROMBOPOIETIN | SPLENECTOMY | CORTICOSTEROID-RESISTANT | eltrombopag | HIGH-DOSE DEXAMETHASONE | drug combinations | immunosuppressive agents | THERAPY | drug synergism | romiplostim | HEMATOLOGY | rituximab | Blood platelets | Blood diseases | Drug therapy | Immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Tailored Prophylaxis in Mexican Pediatric Patients with Hemophilia a By Determining the Pharmacokinetics of Factor VIII
by Estrada, Emma Lizeth and Villarreal, Laura and Mares-Gil, José Eduardo and Blasquez, Edith and García, Daniel Alejandro and Gomez-Almaguer, David
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4922 - 4922
Introduction. Prophylactic replacement of factor VIII (FVIII) is the gold standard for the management of severe hemophilia, preventing bleeding and its... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico
by Jaime‐Pérez, José Carlos and Heredia‐Salazar, Alberto Carlos and Cantú‐Rodríguez, Olga G and Gutiérrez‐Aguirre, Homero and Villarreal‐Villarreal, César Daniel and Mancías‐Guerra, Consuelo and Herrera‐Garza, José Luís and Gómez‐Almaguer, David
The Oncologist, ISSN 1083-7159, 04/2015, Volume 20, Issue 4, pp. 386 - 392
Background and Objective. Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost... 
Hematopoietic stem cell transplant | HSCT cost containment | HSCT cost structure | HSCT costs | HSCT in developing countries | Out‐of‐pocket expenses | BLOOD PROGENITOR-CELL | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | CONDITIONING REGIMENS | CANCER | CHILDREN | REDUCED-INTENSITY | ECONOMIC-EVALUATION | ONCOLOGY | HIGH-DOSE REGIMENS | MYELOGENOUS LEUKEMIA | Out-of-pocket expenses | Thalassemia - therapy | Costs and Cost Analysis | Lymphoma, Non-Hodgkin - therapy | Humans | Female | Male | Mexico | Treatment Outcome | Developing Countries | Hematopoietic Stem Cell Transplantation - economics | Transplantation, Homologous - economics | Leukemia, Myeloid, Acute - therapy | Global Health and Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Treatment of diffuse large B‐cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10‐year results at a Latin American center
by Jaime‐Pérez, José C and Padilla‐Medina, José R and Salazar‐Cavazos, Lorena and Fernández, Lucía T and Gómez‐Almaguer, David
Hematological Oncology, ISSN 0278-0232, 04/2019, Volume 37, Issue 2, pp. 226 - 229
HODGKIN | CHOP | ONCOLOGY | HEMATOLOGY | ELDERLY-PATIENTS | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Age Factors | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Rituximab - administration & dosage | Anthracyclines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Vincristine - administration & dosage | Mexico | Aged | Heart Diseases - chemically induced | Doxorubicin - administration & dosage | Aged patients | Care and treatment | Anthracyclines | Rituximab | Anthracycline | Lymphocytes B | Lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Does Outcomes of HSCT Differ According to Patients’ Socioeconomic Status? Real-World Data from an Outpatient-Based Center in Mexico
by Bugarin-Estrada, Emmanuel and Colunga-Pedraza, Perla Rocío and Gómez-De León, Andrés and Barrera-Salinas, Rebeca and Santana-Hernández, Paola and Gómez-Almaguer, David
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S320 - S321
From August 2017 to May 2018, adult patients who received an HSCT and continued follow-up in our unit were recruited. They were enrolled into one of two... 
Medical research | Social classes | Patient outcomes | Analysis | Leukemia | Medicine, Experimental | Developing countries | Lymphomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Difference between Recollection Day and Basal DHL As a Predictor of Apheresis CD34+ Yield
by Santana-Hernández, Paola and De León, Andrés Gómez and Colunga-Pedraza, Perla Rocío and Salazar-Riojas, Rosario and Valdes-Galvan, Mayra Judith and Gómez-Almaguer, David
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S206 - S207
The preapheresis peripheral blood CD34+ cell count (PBCD34) is the most important predictor of a good mobilization. Flow cytometry is not always immediately... 
Medicine, Experimental | Medical research | Lymphomas | Medical examination | Blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Assessing Patients’ Knowledge and Attitudes Towards HSCT in an Outpatient-Based Transplant Center in Mexico
by Bugarin-Estrada, Emmanuel and De León, Andrés Gómez and Yáñez-Reyes, José Miguel and Colunga-Pedraza, Perla Rocío and Gómez-Almaguer, David
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S301 - S301
We aim to assess knowledge and attitudes in HSCT candidates regarding their diagnosis, prognosis and treatment including HSCT. Since December 2017, all new... 
Medicine, Experimental | Medical research | Health care industry | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Real‐world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America
by Jaime‐Pérez, José C and Jiménez‐Castillo, Raúl A and Pinzón‐Uresti, Mónica A and Cantú‐Rodríguez, Olga G and Herrera‐Garza, José L and Marfil‐Rivera, Luis J and Gómez‐Almaguer, David
Pediatric Blood & Cancer, ISSN 1545-5009, 07/2017, Volume 64, Issue 7, p. n/a
Objective There is a paucity of the studies of adolescents with acute lymphoblastic leukemia (ALL). This is more noticeable in low‐ and middle‐income... 
adolescence | acute lymphoblastic leukemia | adherence | compliance | survival rates | YOUNG-ADULTS | SURVIVAL | PEDIATRIC PROTOCOL | CHILDHOOD | CANCER | CHILDRENS ONCOLOGY GROUP | CHEMOTHERAPY | THERAPY | ONCOLOGY | PEDIATRICS | EXPERIENCE | HEMATOLOGY | AGE | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Treatment Outcome | Remission Induction | Latin America | Young Adult | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Female | Developing Countries | Neoplasm Recurrence, Local - epidemiology | Retrospective Studies | Longitudinal Studies | Adolescence | Acute lymphocytic leukemia | Drug therapy | Analysis | Pediatrics | Toxicity | Leukemia | Central nervous system | Income | Risk | Nervous system | Abandonment | Prevention | Bone marrow | Remission | Teenagers | Diagnosis | Adolescents | Age | Failure | Neutropenia | Acute lymphatic leukemia | Risk groups | Mortality | International standardization | Regression analysis | Lymphatic leukemia | Patients | Survival | Adhesion | Standards | International standards | Death | Environment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting
by Ruiz‐Argüelles, Guillermo J and Gomez‐Almaguer, David and Steensma, David P
American Journal of Hematology, ISSN 0361-8609, 09/2012, Volume 87, Issue 9, pp. 941 - 941
HIGH-DOSE BUSULFAN | HEMATOLOGY | Busulfan - adverse effects | Seizures - prevention & control | Busulfan - therapeutic use | Administration, Oral | Humans | Anticonvulsants - therapeutic use | Hematopoietic Stem Cell Transplantation | Anticonvulsants - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Antineoplastic Agents, Alkylating - administration & dosage | Busulfan - administration & dosage | Seizures - chemically induced | Antineoplastic Agents, Alkylating - therapeutic use | Dose-Response Relationship, Drug | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Transplantation Conditioning - methods | Antineoplastic Agents, Alkylating - adverse effects | Stem cells | Busulfan | Seizures (Medicine)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Tocilizumab for Prophylaxis of Cytokine Release Syndrome after Outpatient-Based Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation
by Marquez, Oscar and Gómez-De León, Andrés and Colunga Pedraza, Perla R and Pezina Cantú, Cesar O and Garcia-Camarillo, Diana E and Santana-Hernandez, Paola and Gutierrez-Aguirre, Cesar Homero and Gomez-Almaguer, David
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5624 - 5624
Introduction Cytokine release syndrome (CRS) is a common and potentially severe toxicity associated with haploidentical peripheral blood hematopoietic stem... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting
by Jimenez-Antolinez, Yajaira Valentine and Colunga Pedraza, Julia Esther and Mares-Gil, José Eduardo and Estrada, Emma Lizeth and Gonzalez-Diaz, Jesus Mauricio and Gomez-Almaguer, David and Gonzalez Llano, Oscar
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5075 - 5075
Introduction Pediatric acute Lymphoblastic Leukemia (ALL) patients have about 90% overall survival (OS) in developed countries. However, many children in... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Aspicular Bone Marrow Aspiration: A Common, but Not a Minor Problem
by Hawing, Jose Angel and Cantu Rodriguez, Olga Graciela and Gómez-De León, Andrés and Mancias, Consuelo and Tarín Arzaga, Luz del Carmen and Gomez-Almaguer, David
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5841 - 5841
Bone marrow (BM) aspiration plays an important role in hematologic malignancies diagnosis. Access and cost of diagnostic flow cytometry remains a problem in... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL
by Rego, Eduardo M and Kim, Haesook T and Ruiz-Argüelles, Guillermo J and Undurraga, Maria Soledad and Del Rosario Uriarte, Maria and Jacomo, Rafael H and Gutiérrez-Aguirre, Homero and Melo, Raul A. M and Bittencourt, Rosane and Pasquini, Ricardo and Pagnano, Katia and Fagundes, Evandro M and De Lourdes Chauffaille, Maria and Chiattone, Carlos S and Martinez, Lem and Meillón, Luis A and Gómez-Almaguer, David and Kwaan, Hau C and Garcés-Eisele, Javier and Gallagher, Robert and Niemeyer, Charlotte M and Schrier, Stanley L and Tallman, Martin and Grimwade, David and Ganser, Arnold and Berliner, Nancy and Ribeiro, Raul C and Lo-Coco, Francesco and Löwenberg, Bob and Sanz, Miguel A
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 11, pp. 1935 - 1943
Thanks to modern treatment with all-trans retinoic acid and chemotherapy, acute promyelocytic leukemia (APL) is now the most curable type of leukemia. However,... 
RISK-ADAPTED TREATMENT | RT-PCR ANALYSIS | ALPHA FUSION GENE | ANTHRACYCLINE MONOCHEMOTHERAPY | TRANS-RETINOIC ACID | EARLY DEATH RATE | CLINICAL-FEATURES | HEMATOLOGY | AGENT ARSENIC TRIOXIDE | MINIMAL-RESIDUAL-DISEASE | REMISSION INDUCTION | Community Networks - organization & administration | Prognosis | Quality Improvement - organization & administration | Leukemia, Promyelocytic, Acute - therapy | Mexico - epidemiology | Developing Countries - statistics & numerical data | Humans | Middle Aged | Male | Treatment Outcome | Consensus | Young Adult | Disease-Free Survival | Internationality | Adolescent | Leukemia, Promyelocytic, Acute - mortality | Survival Analysis | Adult | Female | Leukemia, Promyelocytic, Acute - diagnosis | Uruguay - epidemiology | Aged | Chile - epidemiology | Brazil - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Hospitalization rate and costs in acute lymphoblastic leukemia of childhood in a low‐income group: Financial impact in Northeast Mexico
by Jaime‐Pérez, José Carlos and Fernández, Lucía Teresa and Jiménez‐Castillo, Raúl Alberto and Colunga‐Pedraza, Julia Esther and Padilla‐Medina, José Ramón and Mancías‐Guerra, Consuelo and Gómez‐Almaguer, David
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2017, Volume 64, Issue 12, pp. e26673 - n/a
Background Acute lymphoblastic leukemia (ALL) is one of the main and most expensive and prolonged causes of hospitalization for childhood cancer. We describe... 
length of stay | costs | hospitalization | low‐income | acute lymphoblastic leukemia | popular medical insurance | low-income | CHARGES | LENGTH-OF-STAY | CANCER | CARE | CHILDREN | ONCOLOGY | PEDIATRICS | EXPERIENCE | HEMATOLOGY | Hospital Costs | Length of Stay | Humans | Income | Child, Preschool | Hospitalization - statistics & numerical data | Infant | Intensive Care Units, Pediatric | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adolescent | Female | Retrospective Studies | Child | Longitudinal Studies | Hospitalization - economics | Medicine, Experimental | Medical research | Children | Acute lymphocytic leukemia | Health aspects | Low income groups | Health care | Pediatrics | Costs | Acute lymphatic leukemia | Risk groups | Leukemia | Risk | Lymphatic leukemia | Patients | Age | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis
by Wood, William A and Brazauskas, Ruta and Hu, Zhen-Huan and Abdel-Azim, Hisham and Ahmed, Ibrahim A and Aljurf, Mahmoud and Badawy, Sherif and Beitinjaneh, Amer and George, Biju and Buchbinder, David and Cerny, Jan and Dedeken, Laurence and Diaz, Miguel Angel and Freytes, Cesar O and Ganguly, Siddhartha and Gergis, Usama and Almaguer, David Gomez and Gupta, Ashish and Hale, Gregory and Hashmi, Shahrukh K and Inamoto, Yoshihiro and Kamble, Rammurti T and Adekola, Kehinde and Kindwall-Keller, Tamila and Knight, Jennifer and Kumar, Lalit and Kuwatsuka, Yachiyo and Law, Jason and Lazarus, Hillard M and LeMaistre, Charles and Olsson, Richard F and Pulsipher, Michael A and Savani, Bipin N and Schultz, Kirk R and Saad, Ayman A and Seftel, Matthew and Seo, Sachiko and Shea, Thomas C and Steinberg, Amir and Sullivan, Keith and Szwajcer, David and Wirk, Baldeep and Yared, Jean and Yong, Agnes and Dalal, Jignesh and Hahn, Theresa and Khera, Nandita and Bonfim, Carmem and Atsuta, Yoshiko and Saber, Wael and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Centrum för klinisk forskning i Sörmland (CKFD)
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 09/2018, Volume 24, Issue 9, pp. 1928 - 1935
For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening... 
Bone marrow | Health expenditures | Outcome assessment (Health care) | Precursor cell lymphoblastic leukemia-lymphoma | Hematopoietic stem cell transplantation | MORTALITY | SYSTEM | MANAGEMENT | MARROW | ADULTS | IMMUNOLOGY | RECIPIENTS | TRANSPLANTATION | ONCOLOGY | OUTCOMES | HEMATOLOGY | ASSOCIATION | BLOOD | Transplantation | Prognosis | Acute lymphocytic leukemia | Analysis | Hematopoietic stem cells | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Allogeneic peripheral blood stem cell transplantation using reduced‐intensity conditioning in an outpatient setting in ABO‐incompatible patients: are survival and graft‐versus‐host disease different?
by Gutiérrez‐Aguirre, Cesar Homero and Gómez‐De‐León, Andrés and Alatorre‐Ricardo, Julio and Cantú‐Rodríguez, Olga Graciela and González‐Llano, Oscar and Jaime‐Pérez, José Carlos and Mancías‐Guerra, Consuelo and Flores‐Jiménez, Juan Antonio and Gómez‐Almaguer, David
Transfusion, ISSN 0041-1132, 05/2014, Volume 54, Issue 5, pp. 1269 - 1277
Background Graft‐versus‐host disease (GVHD) is a major cause of morbimortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Minor ABO... 
RELAPSE | SINGLE-CENTER EXPERIENCE | IMPACT | RISK-FACTORS | DONOR | BONE-MARROW-TRANSPLANTATION | MALIGNANCIES | GVHD | IMMUNE HEMOLYSIS | HEMATOLOGY | HEMATOPOIETIC TRANSPLANTATION | Peripheral Blood Stem Cell Transplantation - adverse effects | Humans | Middle Aged | Proportional Hazards Models | Child, Preschool | Peripheral Blood Stem Cell Transplantation - mortality | Blood Group Incompatibility - complications | Infant | Logistic Models | Male | Transplantation, Homologous | Outpatients | Graft vs Host Disease - mortality | Adolescent | Adult | Female | Aged | Retrospective Studies | ABO Blood-Group System - immunology | Transplantation Conditioning | Child | Graft vs Host Disease - etiology | Transplantation | Analysis | Hematopoietic stem cells | Stem cells | Transplants & implants | Bone marrow
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights